Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Authors : Alcantara, Marion; Chevrier, Marion; Jardin, Fabrice ...

Subjects: Ibrutinib; Lenalidomide; Phase IB trial

Source: ISSN: 1756-8722 ; Journal of Hematology and Oncology ; https://hal.science/hal-04719756 ; Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Authors : Casulo, Carla; Santoro, Armando; Cartron, Guillaume ...

Subjects: clinical trials; durvalumab; hematologic malignancies

Source: EISSN: 2573-8348 ; Cancer reports ; https://nantes-universite.hal.science/hal-04756714 ; Cancer reports, 2022, 6 (1), pp.e1662. ⟨10.1002/cnr2.1662⟩

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Authors : Casulo, Carla; Santoro, Armando; Cartron, Guillaume ...

Subjects: clinical trials; durvalumab; hematologic malignancies

Source: EISSN: 2573-8348 ; Cancer reports ; https://nantes-universite.hal.science/hal-04756714 ; Cancer reports, 2022, 6 (1), pp.e1662. ⟨10.1002/cnr2.1662⟩

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

اتصل بنا

اتبع